Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Ibio (IBIO) and Sarepta Therapeutics (SRPT)

Tipranks - Tipranks - Thu Feb 26, 4:36PM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ibio (IBIO – Research Report) and Sarepta Therapeutics (SRPT – Research Report).

Claim 50% Off TipRanks Premium

Ibio (IBIO)

In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Ibio, with a price target of $5.00. The company’s shares closed last Wednesday at $2.87.

According to TipRanks.com, Dolezal is a 5-star analyst with an average return of 18.0% and a 45.3% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Kodiak Sciences, and Oculis Holding. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ibio with a $5.00 average price target.

See the top stocks recommended by analysts >>

Sarepta Therapeutics (SRPT)

In a report released today, Ritu Baral from TD Cowen reiterated a Hold rating on Sarepta Therapeutics, with a price target of $17.00. The company’s shares closed last Wednesday at $18.97.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 41.2% and a 55.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Milestone Pharmaceuticals, and Madrigal Pharmaceuticals. ;'>

Currently, the analyst consensus on Sarepta Therapeutics is a Hold with an average price target of $22.27.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).